# BIOEQUIVALENCE SUMMARY TABLES FOR DRUG PARTICLE SIZE DISTRIBUTION (PSD) BY MORPHOLOGICALLY DIRECTED RAMAN SPECTROSCOPY (MDRS)

## **Table 1. Product Batch Information**

	TEST			REFERENCE				
Product Name								
Dosage Form								
Strength								
Manufacturer								
To-be-Marketed Production Batch								
Size								
			Batch/ Lo	ot Size				
Study	Batch/ Lot No.	Potency*	Theoretical (units) -if applicable	Actual (units)	Manufacture Date	Batch/ Lot No.	Potency*	Expiration Date
Morphologically								
Directed Raman								
Spectroscopy (MDRS)								

<sup>\*</sup>Data obtained from Certificate of Analysis

Please add row(s) as needed to list other in vitro/ in vivo bioequivalence study(ies) and include corresponding batch/ lot numbers from each test.

## **Table 2. Study Information**

Study No.				
Study Title				
Study Report Location and Link				
Study Site Name and Address				
Principal Investigator				
Analyst(s)				
Study Dates				
SOR(a)	No.	Title	Effective Date (Revision Date - if any)	Location and Link
SOP(s)				
	·	Pleas	e add row(s) as needed.	

## **Table 3. Method Development**

#### **Table 3.1. Instrument Details**

Type/ Model	
Manufacturer	
Last Performance Qualification (PQ) Date	
Optical Size Range (μm)	
Spectral Range (cm <sup>-1</sup> )	
Spectral Resolution (cm <sup>-1</sup> )	
Size of Scan Area (unit <sup>2</sup> )	
Laser Specification	
a. Wavelength (nm)	

	b. Power Output (mW)						
-	c. Laser Spot Size (μm)						
	Minimum Measurable Par	ticle Size (μm)					
Γable	3.2. Sample Preparation						
I	Method	☐ Wet measure	ement (If "Wet", fill T	able 3.2.a	a)		
		☐ Dry measure	ment (If "Dry", fill T	able 3.2.b	9)		
		☐ Other (please	e specify and provide	relevant i	nformation under Table 3.2)		
	Sample Substrate (plate details with dimensions)						
	Sample Preparation Steps						
	for nasal and orally inhaled						
	drug products please also specify the spray#(s) and						
	ife stage(s), if applicable].						
r	Temperature of the						
	Laboratory Data Location (link for						
	representative images of						
1	prepared sample on plate/						
5	slide)						
able	3.2.a. Wet Sample Prepara	tion					
	Is any pressure applied to t	the cover slip?	□ Yes □ No				
	Is any sealant used?		☐ Yes ☐ No (If "Yes", describe sealant.)				
	Is the sample modified (e.g	., diluent,	☐ Yes ☐ No				
	surfactant, contrasting age native state? *	nt) from its	(If "Yes", please provide location and link of supporting experimental data)				
	Has the sample undergone evaporation or freezing?*	ultrasonication,	☐ Yes ☐ No (If "Yes", please provide location and link of supporting experimental data)				
	Volume of sample used (un	it)					
	Is the volume of sample op	timized? *	☐ Yes ☐ No (If "Yes", please provide location and link of supporting experimental data)				
	Settling time (unit)						
	Is the settling time optimize	ed? *	☐ Yes ☐ No				
	* Dlagga marrida grama artim	a armanimantal d			f experimental data) vant location and link in Table 3.2.a.		
	· Please provide supporting	ig experimental d	ata in the study repor	and refev	vant location and link in Table 3.2.a.		
able	3.2.b. Dry Sample Prepara	tion					
	<b>Dispersion Method</b>						
	Solid Dispersion Unit (SI	OU) Settings (if	Injection Pressur	e (bar)			
	applicable)		Injection Time (	ms)			
			Settling Time (se	ec)			
		Powder volume					
<b>Sable</b>	3.3. Particle Imaging and M	Aorphology Ana	lysis		,		
	Number of Particles Ima	god					
	List of Distinct Morphole		.g., primary particle				
	spherical, rodlike, oval, ne						
	surface, agglomerate, touc	hing particle etc)					
	Percentage (%) of touchi	ng particles? *					

(Please provide detailed information)	
Percentage (%) of aggregates of particles? *	
(Please provide detailed information)	
Data Location (link for individual particle images)	

Table 3.4. Raman Spectrum (Molecular Fingerprinting) and Spectral Classification of API and Excipients

API used for Raman Spectral Library	
Source and Purity of API	
Polymorph of API (if any)	
API Exposure Time (seconds)	
Raman Spectral Region for API (x cm-1 to y cm-1)	
Signature Peaks for API (cm <sup>-1</sup> )	
Excipient(s) Used for Raman Spectral Library	
Excipient(s) Exposure Time (seconds)	
Raman Spectral Region for Excipients (x cm <sup>-1</sup> to y cm <sup>-1</sup> )	
Is there any overlapping peak(s) in signature peak region?	☐ No ☐ Yes (if yes, provide detailed information)
Sample Stage/ Substrate (background spectrum)	
Location and Link for Representative Spectrum of API and	
Excipients (Intensity vs Raman Shift, cm <sup>-1</sup> )	
Cut-off for Raman Spectral Correlation	

## Table 3.5.a. Morphology Filter Selection for T Product

Filter Selection for T Product*								
API	No Filter	Filter(s) combination	Filter(s) combination	Filter(s) combination	Add Columns as needed			
API Particle Count								
<b>Excipient Particle Count</b>								
<b>Total Particle Count</b>								
% API Particles								
# API Particles Removed								
# Excipient Particles Removed								
% API Particles Retained								
% Excipient Particles Removed								
Morphology Filter(s) Combination								
that Adequately Fit for T Product								
Data Location (link for normalized								
distribution curves for API and								
excipients including plots of								
normalized particles count vs								
morphology filter)								

<sup>\*</sup>e.g., Circular equivalent (CE) diameter, aspect ratio/ elongation, circularity, convexity, intensity mean, solidity, etc.

## Table 3.5.b. Morphology Filter Selection for R Product

Filter Selection for R Product*								
API	No Filter	Filter(s) combination	Filter(s) combination	Filter(s) combination	Add Columns as needed			
API Particle Count								
<b>Excipient Particle Count</b>								
<b>Total Particle Count</b>								
% API Particles								
# API Particles Removed								
# Excipient Particles Removed								
% API Particles Retained								
% Excipient Particles Removed								

<sup>\*</sup> Please provide supporting experimental data and images of individual particles in the study report and relevant link and location in Table 3.3.

Morphology Filter(s) Combination
that Adequately Fit for R Product
Data Location (link for normalized
distribution curves for API and
excipients including plots of
normalized particles count vs
morphology filter)
Final Morphology Filter(s)
Combinations Selected that
Adequately Fit for both T and R
Products

<sup>\*</sup>e.g., Circular equivalent (CE) diameter, aspect ratio/ elongation, circularity, convexity, intensity mean, solidity, etc.

Table 3.6. Determination of Minimum Number of Particles to be Measured

Was API Particle Size Distribution Measured with Different				□ No □ Yes			
Particles Count?				(if yes, provide following information)			
Program/ Software Used				=			
Particle Count	Particle Count N D10(μm) D50(μm)				Dmean(µm)	SPAN	
		Mean ± %RSD	Mean ± %RSD	Mean ± %RSD	Mean ± %RSD	Mean ± %RSD	
		Mean ± %RSD	Mean ± %RSD	Mean ± %RSD	Mean ± %RSD	Mean ± %RSD	
		Mean ± %RSD	Mean ± %RSD	Mean ± %RSD	Mean ± %RSD	Mean ± %RSD	
		Mean ± %RSD	Mean ± %RSD	Mean ± %RSD	Mean ± %RSD	Mean ± %RSD	
		Mean ± %RSD	Mean ± %RSD	Mean ± %RSD	Mean ± %RSD	Mean ± %RSD	
Please add additional row(s) as needed							
<b>Optimized Partic</b>	les Count S	Selected for Final N	Method				

#### **Table 4: Final MDRS Method Parameters**

Sample Carrier	
Illumination	
Cal Intensity	
Optics (Magnification)	
Type of Focus	
Threshold	
Trash Size (pixels)	
Scan Area	
Hole Filling	
Morphology Filters	Circular equivalent (CE) Diameter:
	Aspect ratio/ Elongation:
	Circularity:
	Intensity Mean:
	Convexity:
	Solidity:
Particle Number	·
Exposure Time	
Number of Co-adds	
Low Laser Power	
Chemical Library	
Chemical Analysis	
Pre-processing	
Raman Correlation Score	
NT / TC 1 /1 1	41 1/ ) C DCD

Note: If you used any orthogonal method(s) for PSD measurement of active ingredient particles that are not suitable for evaluation by MDRS, please provide detailed study report and relevant BE summary tables for the orthogonal method separately. The orthogonal method(s) for PSD measurement should be validated appropriately and the validation report should be submitted.

## **Table 5: Method Validation**

Table 5.1. Accuracy\*

Size (known) of Standard Particles (unit)	X1 (unit)	X2 (unit)	X3 (unit)	X4 (unit)	Add columns as needed
Measurements			CE Diameter	(unit)	us needed
1					
2					
3					
Mean					
SD					
%RSD					
Location and link of performance qualification (PQ) data					

<sup>\*</sup> Please provide performance qualification (PQ) data less than a year old at the time of study along with the study report and provide location and link in Table 5.1.

**Table 5.2. Precision** 

RLD/RS Product Batch/ Lot (with expiration date) # Used for Method Validation	
For nasal and orally inhaled drug products please also specify the spray#(s) and life stage(s), if applicable.	

Replicates		CE Diameter (unit)			
	Dv10	Dv50	Dv90	SPAN	
1					
2					
3					
4					
5					
6					
Mean (N=)					
SD					
%RSD					
Range					

**Table 5.2.a. Intermediate Precision (By Date)** 

Day 1					
Replicates		CE Diameter (unit)			
	Dv10	Dv50	Dv90	SPAN	
1					
2					
3					
4					
5					
6					
Mean (N=)					
SD					
%RSD					
Range					
		Day 2			
Replicates		CE Diameter (unit)			
	Dv10	Dv50	Dv90	SPAN	
1					
2					

3		
4		
5		
6		
Mean (N=)		
SD		
%RSD		
Range		
% Difference		
between Means of		
Day 1 and Day 2		
Inter-day %RSD		

Table 5.2.b. Intermediate Precision (By Analyst)

		Analyst 1		
Replicates		CE Diameter (unit)		
	Dv10	Dv50	Dv90	SPAN
1				
2				
3				
4				
5				
6				
Mean (N=)				
SD				
%RSD				
Range				
		Analyst 2		
Replicates		CE Diameter (unit)		
	Dv10	Dv50	Dv90	SPAN
1				
2				
3				
4				
5				
6				
Mean (N=)				
SD				
%RSD				
Range				
% Difference				
between Means by				
Analyst 1 and				
Analyst 2				
Inter Analyst %RSD				

Table 5.3. Specificity

Placebo*					
Replicates		CE Diameter (unit)			
	Dv10	Dv50	Dv90	SPAN	
1					
2					
3					
4					
5					
6					
Mean (N=)					
SD					

%RSD				
Range				
		Placebo Spiked with AP		
Replicates		CE Diameter (unit)		
	Dv10	Dv50	Dv90	SPAN
1				
2				
3				
4				
5				
6				
Mean (N=)				
SD				
%RSD				
Range				

<sup>\*</sup> Please provide composition and manufacturing details of placebo and Raman spectrum (overlay) of background, placebo and placebo spiked with API in the report. Please identify the characteristic peak(s) for placebo and API and submit relevant particle images in the study report. Please provide relevant location and link of images in Table 5.3.

#### **Table 5.4. Robustness**

Table 5.4.a. Altered Sample Amount/ Volume (if applicable)

Altered Conditions	CE Diameter (unit)			
	Dv10	Dv50	Dv90	SPAN
Sample Amount/ Volume-1 (N=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Sample Amount/ Volume-2 (N=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Sample Amount/ Volume-3 (N=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Mean (N=)				
SD				
%RSD				
Range				

Table 5.4.b. Altered Scan Area (if applicable)

Altered Conditions	CE Diameter (unit)			
	Dv10	Dv50	Dv90	SPAN
Scan Area-1 (N=6)	Mean ± SD	Mean ± SD	$Mean \pm SD$	Mean ± SD
Scan Area-2 (N=6)	Mean ± SD	Mean ± SD	$Mean \pm SD$	Mean ± SD
Scan Area-3 (N=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Mean (N=)				
SD				
%RSD				
Range				

**Table 5.4.c. Altered Settling Time (if applicable)** 

Altered Conditions	CE Diameter (unit)			
	Dv10	Dv50	Dv90	SPAN
Settling Time-1 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Settling Time-2 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Settling Time-3 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Mean (N=)				
SD				
%RSD				
Range				

**Table 5.4.d. Altered Threshold Selection (if applicable)** 

Altered Conditions	CE Diameter (unit)			
	Dv10	Dv50	Dv90	SPAN
Threshold-1 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Threshold-2 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Threshold-3 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Mean (N=)				
SD				
%RSD				
Range				

**Table 5.4.e. Altered Percent Overlap (if applicable)** 

Altered Conditions	CE Diameter (unit)			
	Dv10	Dv50	Dv90	SPAN
Percent Overlap-1 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Percent Overlap-2 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Percent Overlap-3 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Mean (N=)				
SD				
%RSD				
Range				

**Table 5.4.f. Altered Particle Count (if applicable)** 

Altered Conditions	C	CE Diameter (unit)					
	Dv10	Dv50	Dv90	SPAN			
Particle Count-1 (n=6)	$Mean \pm SD$	Mean ± SD	$Mean \pm SD$	Mean ± SD			
Particle Count-2 (n=6)	$Mean \pm SD$	Mean ± SD	$Mean \pm SD$	Mean ± SD			
Particle Count-3 (n=6)	$Mean \pm SD$	Mean ± SD	$Mean \pm SD$	Mean ± SD			
Mean (N=)							
SD							
%RSD							
Range							

**Table 5.4.g. Altered Morphology Filters Combinations (if applicable)** 

Altered Conditions	C			
	Dv10	Dv50	Dv90	SPAN
Combination-1 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Combination-2 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Combination-3 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Combination-4 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Combination-5 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Combination-6 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Mean (N=)				
SD				
%RSD				
Range				

**Table 5.4.h. Altered Correlation Score (if applicable)** 

Altered Conditions	C			
	Dv10	Dv50	Dv90	SPAN
Correlation Score-1 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Correlation Score-2 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Correlation Score-3 (n=6)	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
Mean (N=)				
SD				
%RSD				
Range				

Table 5.4.i. Acceptance Criteria defined by SOP

Validation Parameters	Acceptance Criteria
Accuracy	
Precision	
•	
•	
Intermediate Precision by Date	
Intermediate Precision by Analyst	
Specificity	
Robustness	

Table 6. Pivotal Particle Size Distribution by MDRS

D <sub>50</sub> Summary										
		Me	an	Variability (%CV)				Mean Ratio (T/R)		
		Arith	Geo	Within Lot (n=10)			Between Lot (n=30)	Total (n=30)	Arith (n=30)	Geo (n=30)
				Lot 1 Lot 2 Lot 3						
BEG *	Test									
END*										
BEG*	Ref									
END*										

SPAN Summary													
		Me	an	Variability (%CV)			hility (%( 'V)		Ratio (R)				
		Arith	Geo	Within Lot (n=10)						Between Lot (n=30)	Total (n=30)	Arith (n=30)	Geo (n=30)
				Lot 1 Lot 2 Lot 3									
BEG *	Test												
END*													
BEG*	Ref									·			
END*													

<sup>\*</sup>Please include individual life stage data as applicable.

**Table 7: Summary of Population Bioequivalence Results** 

Variable	Mean (log Scale)		Mean Difference (log Scale)	Standard	Deviation	Sigma T/ Sigma R Ratio
	Test	Reference	(log Scale)	Sigma T	Sigma R	
Dv50						
Scaled	Linearized Point Estimate		95% Upper Co	nfidence Bound	Pass or l	Fail PBE
Reference scaled						
Constant-scaled	_					

Variable	Mean (log Scale)		Mean Difference	Standard	Deviation	Sigma T/ Sigma R Ratio
	Test	Reference	(log Scale)	Sigma T	Sigma R	
SPAN						
Scaled	Linearized Point Estimate		95% Upper Co	nfidence Bound	Pass or 1	Fail PBE
Reference scaled						
Constant-scaled						